Research map: Predictive Biomarkers of Systemic Therapy Response in Cutaneous Melanoma

Back to the article

Papers in this map

  1. Overall Survival with Combined Nivolumab and Ipilimumab in Advanced Melanoma · Jedd D. Wolchok · 2017 · 5454 citations · Cited by this paper
  2. Trans-Presentation of IL-15 by IL15Rα Attenuates Tumor Immune Surveillance and Is Dispensable for IL-15-Dependent Tumor Growth Control · 2026 · Related
  3. Nivolumab in Previously Untreated Melanoma without BRAF Mutation · Caroline Robert · 2014 · 5444 citations · Cited by this paper
  4. Survivorship Challenges in Metastatic Prostate Cancer in the Era of Prolonged Survival: A Review · 2026 · Related
  5. Exosomal PD-L1 contributes to immunosuppression and is associated with anti-PD-1 response · Gang Chen · 2018 · 2874 citations · Cited by this paper
  6. Factors Associated with the Timing of Liver Metastasis After Colorectal Cancer Surgery: A Retrospective Multicenter Study · 2026 · Related
  7. Tumor and Microenvironment Evolution during Immunotherapy with Nivolumab · Nadeem Riaz · 2017 · 2638 citations · Cited by this paper
  8. Mapping Misconceptions in Neuroendocrine Tumor Nomenclature: A Scoping Review of National Database Studies and Clinical Implications · 2026 · Related
  9. Adjuvant Nivolumab versus Ipilimumab in Resected Stage III or IV Melanoma · Jeffrey S. Weber · 2017 · 2252 citations · Cited by this paper
  10. Interpreting Circulating Bile Acid Profiles in Pancreatic Cancer: The Role of Cholestasis and Its Management · 2026 · Related
  11. Adjuvant Dabrafenib plus Trametinib in Stage III BRAF -Mutated Melanoma · Georgina Venetia Long · 2017 · 1504 citations · Cited by this paper
  12. Ex Vivo Line-Field Confocal Optical Coherence Tomography and Ex Vivo Fusion Confocal Microscopy for Lateral-Margin Assessment of Basal Cell Carcinoma in Correlation with Histopathology: A Prospective Pilot Diagnostic-Accuracy Study · 2026 · Related
  13. Liquid biopsy enters the clinic — implementation issues and future challenges · Michail Ignatiadis · 2021 · 1217 citations · Cited by this paper
  14. Burden, Trends, and Future Projections of Multiple Myeloma in China from 1990 to 2023 · 2026 · Related
  15. Robust prediction of response to immune checkpoint blockade therapy in metastatic melanoma · Noam Auslander · 2018 · 833 citations · Cited by this paper
  16. PTEN Protein Loss in Diagnostic Prostate Biopsies Is Associated with Gleason Score Upgrading in Radical Prostatectomy · 2026 · Related
  17. Cancer biomarkers: Emerging trends and clinical implications for personalized treatment · Antonio Passaro · 2024 · 663 citations · Cited by this paper
  18. Digital Nutritional Care in Oncology: Opportunities to Enhance Quality of Life and Support Patient-Centered Care · 2026 · Related
  19. The eighth edition American Joint Committee on Cancer (AJCC) melanoma staging system: implications for melanoma treatment and care · Emily Zhi-Yun Keung · 2018 · 603 citations · Cited by this paper
  20. Toward Microbiome-Informed Melanoma Care: The Gut Microbiota in Melanoma Evolution, Immunotherapy Response and Immune-Related Toxicity · 2026 · Related
  21. Elevated serum interleukin-8 is associated with enhanced intratumor neutrophils and reduced clinical benefit of immune-checkpoint inhibitors · Kurt Alex Schalper · 2020 · 566 citations · Cited by this paper
  22. Changes in serum interleukin-8 (IL-8) levels reflect and predict response to anti-PD-1 treatment in melanoma and non-small-cell lung cancer patients · Miguel F. Sanmamed · 2017 · 469 citations · Cited by this paper
  23. Early B cell changes predict autoimmunity following combination immune checkpoint blockade · Rituparna Das · 2018 · 439 citations · Cited by this paper
  24. Phase II Trial (BREAK-2) of the BRAF Inhibitor Dabrafenib (GSK2118436) in Patients With Metastatic Melanoma · Paolo A. Ascierto · 2013 · 433 citations · Cited by this paper
  25. Molecular testing for BRAF mutations to inform melanoma treatment decisions: a move toward precision medicine · Liang Cheng · 2017 · 417 citations · Cited by this paper
  26. Circulating Cytokines Predict Immune-Related Toxicity in Melanoma Patients Receiving Anti-PD-1–Based Immunotherapy · Su Yin Lim · 2018 · 382 citations · Cited by this paper
  27. Serum lactate dehydrogenase as an early marker for outcome in patients treated with anti-PD-1 therapy in metastatic melanoma · Stefan Diem · 2016 · 315 citations · Cited by this paper
  28. Defining clinically useful biomarkers of immune checkpoint inhibitors in solid tumours · Ashley M. Holder · 2024 · 289 citations · Cited by this paper
  29. Diet-driven microbial ecology underpins associations between cancer immunotherapy outcomes and the gut microbiome · Rebecca C. Simpson · 2022 · 253 citations · Cited by this paper
  30. Current concepts of metastasis in melanoma · Blazej Zbytek · 2008 · 243 citations · Cited by this paper
  31. Peripheral Blood Markers Identify Risk of Immune-Related Toxicity in Advanced Non-Small Cell Lung Cancer Treated with Immune-Checkpoint Inhibitors · Alberto Pavan · 2019 · 238 citations · Cited by this paper
  32. Exosomal circRNA: emerging insights into cancer progression and clinical application potential · Fan Zhang · 2023 · 224 citations · Cited by this paper
  33. Systemic Therapy for Melanoma: ASCO Guideline Update · Rahul Seth · 2023 · 224 citations · Cited by this paper
  34. Circulating tumor DNA: current challenges for clinical utility · Donna Kimberly Dang · 2022 · 223 citations · Cited by this paper
  35. Lactate dehydrogenase: a marker of diminished antitumor immunity · Sandra van Wilpe · 2020 · 220 citations · Cited by this paper
  36. Correlation of BRAF Mutation Status in Circulating-Free DNA and Tumor and Association with Clinical Outcome across Four BRAFi and MEKi Clinical Trials · Ademi Santiago-Walker · 2015 · 205 citations · Cited by this paper
  37. Association BetweenNRASandBRAFMutational Status and Melanoma-Specific Survival Among Patients With Higher-Risk Primary Melanoma · Nancy E. Thomas · 2015 · 196 citations · Cited by this paper
  38. Prediction and monitoring of relapse in stage III melanoma using circulating tumor DNA · Lavinia Tan · 2019 · 196 citations · Cited by this paper
  39. BRAF Mutations in Melanoma: Biological Aspects, Therapeutic Implications, and Circulating Biomarkers · Giorgia Castellani · 2023 · 187 citations · Cited by this paper

Source: OpenAlex (CC0)